Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Teladoc Health, Inc.TDOC · Entity 1547 | Director | May 17, 2022 | May 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Teladoc Health, Inc.
Report date May 17, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,195 |
Reported balance
After 2022-05-17 transaction · row 1
1 source rowRow 1 · 2022-05-17 · Exercise / conversion · Acquired 1,638 · Balance 7,195 F1: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-17 · Exercise / conversion · Disposed 1,638 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F3: On May 17, 2021, the reporting person was granted 1,638 restricted stock units, vesting in full on May 17, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.
F2: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.
F3: On May 17, 2021, the reporting person was granted 1,638 restricted stock units, vesting in full on May 17, 2022.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Livongo Health, Inc.
Report date October 30, 2020 · Filed October 30, 2020
Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 1
1 source rowRow 1 · 2020-10-30 · Disposition to issuer · Disposed 8,142 · Balance 0 F1: Includes 3,107 restricted stock units ("RSUs"). F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F3: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 3,107 restricted stock units ("RSUs").
F2: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).
F3: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).
F4: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2022 Filed May 18, 2022 20:19 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 1,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-005232 · form4-05182022_010526.xml · derivative · entry 2 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F3 · derivative.exercise_date: On May 17, 2021, the reporting person was granted 1,638 restricted stock units, vesting in full on May 17, 2022. F3 · derivative.expiration_date: On May 17, 2021, the reporting person was granted 1,638 restricted stock units, vesting in full on May 17, 2022. Read SEC document |
| May 17, 2022 Filed May 18, 2022 20:19 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 1,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-005232 · form4-05182022_010526.xml · nonDerivative · entry 1 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 436 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005436 · form4-11232021_011115.xml · derivative · entry 2 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 872 Underlying: Common Stock · 436 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F3 · derivative.exercise_date: The restricted stock unit vests in three substantially equal annual installments beginning November 19, 2021. F3 · derivative.expiration_date: The restricted stock unit vests in three substantially equal annual installments beginning November 19, 2021. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 436 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-21-005436 · form4-11232021_011115.xml · nonDerivative · entry 1 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 715 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005969 · edgar.xml · derivative · entry 2 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F3 · derivative.exercise_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. F3 · derivative.expiration_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:11 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 715 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-005969 · edgar.xml · nonDerivative · entry 1 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| May 17, 2021 Filed May 18, 2021 20:15 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GrantRestricted Stock Units · Derivative | 1,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005486 · edgar.xml · derivative · entry 1 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,638 Underlying: Common Stock · 1,638 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on the earlier of (i) May 17, 2022 and (ii) the day immediately preceding the issuer's 2022 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest in full on the earlier of (i) May 17, 2022 and (ii) the day immediately preceding the issuer's 2022 annual meeting of stockholders. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:28 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 713 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002336 · edgar.xml · derivative · entry 2 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 715 Underlying: Common Stock · 713 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F3 · derivative.exercise_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. F3 · derivative.expiration_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:28 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 713 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-002336 · edgar.xml · nonDerivative · entry 1 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 21:05 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionRestricted Stock Units · Derivative | 713 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011462 · edgar.xml · derivative · entry 2 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 Underlying: Common Stock · 713 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F3 · derivative.exercise_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. F3 · derivative.expiration_date: The restricted stock units vest in three substantially equal installments each quarter beginning November 25, 2020. Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 21:05 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | Exercise / conversionCommon Stock | 713 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-20-011462 · edgar.xml · nonDerivative · entry 1 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Read SEC document |
| November 19, 2020 Filed Nov 20, 2020 21:41 UTC | Teladoc Health, Inc. TDOC · Entity 1547 | GrantRestricted Stock Units · Derivative | 1,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-011266 · edgar.xml · derivative · entry 1 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,308 Underlying: Common Stock · 1,308 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TDOC common stock. F2 · derivative.exercise_date: The restricted stock unit vests in three substantially equal annual installments beginning November 19, 2021. F2 · derivative.expiration_date: The restricted stock unit vests in three substantially equal annual installments beginning November 19, 2021. Read SEC document |
| October 30, 2020 Filed Oct 30, 2020 17:23 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Disposition to issuerCommon Stock | 8,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001639225-20-000065 · wf-form4_160409300188625.xml · nonDerivative · entry 1 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 3,107 restricted stock units ("RSUs"). F2 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F3 · price: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F4 · price: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. Read SEC document |
| May 19, 2020 Filed May 29, 2020 18:30 UTC | Livongo Health, Inc. LVGO · Entity 145566 | GrantCommon Stock | 4,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-033040 · doc4.xml · nonDerivative · entry 1 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,142 F1 · shares: The reported shares are represented by restricted stock units which vest in four equal quarterly installments beginning on August 25, 2020. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 19:22 UTC | Livongo Health, Inc. LVGO · Entity 145566 | PurchaseCommon Stock | 4,000 | $25.48 | $101,920.00 |
DisclosureSEC source: 0000899243-19-027553 · doc4.xml · nonDerivative · entry 1 Bischoff Christopher · CIK 0001783106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.